Celltrion announced on the 21st that it has decided to conduct an additional stock buyback worth about 100 billion won through a board meeting. The total amount of stock buybacks this year has reached approximately 750 billion won over eight instances, while the total amount of stock cancellations is about 900 billion won. It plans to proceed via on-market purchases starting from the 22nd.
Earlier, on the 4th, Celltrion Holdings, the holding company of the Celltrion Group, also secured new funding and decided to purchase a total of 500 billion won worth of Celltrion shares in two batches to enhance corporate value. In April, Celltrion Holdings also acquired 100 billion won worth of Celltrion shares, and Seo Jung-jin, the chairman of the Celltrion Group, along with the subsidiary Celltrion Skin Cure, each decided to acquire shares worth 50 billion won. All employees also participated in a stock purchase amounting to around 40 billion won.
Along with returning value to shareholders, Celltrion has also worked to enhance corporate value. Last year, it achieved its largest ever annual revenue of 3.5573 trillion won, followed by a record high in the first quarter of this year. The second quarter report, which was disclosed on this day, also showed significant growth in both revenue and operating profit.
A representative of Celltrion said, "This decision to buy back shares demonstrates our commitment to growing together with investors based on confidence in the company's future value," adding, "We will accelerate our leap into a 'global big pharma' through an active shareholder return policy, continuous innovation, and expansion of our global market share."